Grant Angus 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Aug 13, 2024
Insider Transaction Report
Form 4
Grant Angus
EVP, Business Development
Transactions
- Exercise/Conversion
Ordinary Shares
2024-08-09+12,913→ 12,913 total - Sale
Ordinary Shares
2024-08-09$17.28/sh−4,065$70,243→ 8,848 total - Exercise/Conversion
Restricted Share Units
2024-08-09−12,913→ 38,739 total→ Ordinary Shares (12,913 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]Restricted share units were granted on August 9 ,2023, with 12,913 vesting on each of August 9, 2024, August 9, 2025, August 9, 2026 and August 9, 2027.